Hosted on MSN1mon
Study Finds Exenatide Not Beneficial for Parkinson Disease
FRIDAY, Feb. 7, 2025 (HealthDay News) -- The glucagon-like peptide-1 receptor agonist exenatide does not yield ... exenatide 2 mg by subcutaneous pen injection once per week over 96 weeks or ...
pharmaphorum8d
AstraZeneca improves diabetes pen to maintain its market share
AstraZeneca announced that the EC green-lighted the new formulation of the once-weekly type-2 diabetes injection, which will be marketed as Bydureon BCise (exenatide 2mg prolonged-release suspension).
Hosted on MSN1mon
Ozempic-like jab 'fails' for millions with condition, study finds
Experts had hoped a medication called exenatide, a weight loss jab in the same class of drugs as Ozempic and Wegovy, could help combat the degenerative nerve condition. But University College of ...
Medscape9d
Short-term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes
Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...